Chemomab Therapeutics Ltd. (CMMB) Income Statement Analysis

See more : Pritish Nandy Communications Ltd (PNC.NS) Income Statement Analysis – Financial Results

Complete financial analysis of Chemomab Therapeutics Ltd. (CMMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemomab Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Chemomab Therapeutics Ltd. (CMMB)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.chemomab.com

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2012
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	66.83K	57.77K	34.02K	80.00K	281.91K	66.00K	51.00K	40.64K	26.25K	0.00
Gross Profit	-66.83K	-57.77K	-34.02K	-80.00K	-281.91K	-66.00K	-51.00K	-40.64K	-26.25K	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	18.38M	16.98M	6.33M	4.68M	13.35M	7.51M	6.23M	2.34M	5.96M	15.72M
General & Administrative	7.08M	11.56M	6.03M	1.29M	960.00K	374.00K	0.00	0.00	0.00	5.65M
Selling & Marketing	0.00	0.00	0.00	0.00	5.96M	5.08M	0.00	0.00	0.00	0.00
SG&A	7.08M	11.56M	6.03M	1.29M	5.98M	5.46M	3.11M	2.25M	1.14M	5.65M
Other Expenses	0.00	0.00	0.00	749.00K	3.35M	0.00	0.00	0.00	0.00	0.00
Operating Expenses	25.46M	28.53M	12.37M	5.97M	19.33M	12.97M	9.34M	4.59M	7.11M	21.37M
Cost & Expenses	25.46M	28.53M	12.37M	5.97M	19.61M	13.04M	9.39M	4.63M	7.13M	21.37M
Interest Income	1.23M	351.62K	65.00	20.00K	393.00K	0.00	1.00K	521.00	1.03K	0.00
Interest Expense	0.00	353.00K	111.08K	6.00K	9.00K	0.00	5.00K	0.00	14.16K	0.00
Depreciation & Amortization	67.00K	57.77K	34.02K	80.00K	281.91K	66.00K	51.00K	40.64K	26.25K	0.00
EBITDA	-25.39M	-28.48M	-12.33M	-5.95M	-26.92M	-13.36M	-9.50M	-4.57M	-7.46M	24.18M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-25.46M	-28.53M	-12.40M	-5.97M	-19.61M	-13.04M	-9.39M	-4.63M	-7.13M	24.18M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.24M	353.00K	-111.00K	21.00K	-7.60M	-455.52K	-164.63K	20.69K	-367.79K	29.24M
Income Before Tax	-24.22M	-28.18M	-12.48M	-5.95M	-27.21M	-13.49M	-9.48M	-4.60M	-7.50M	24.18M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-534.00K	77.00K	-21.00K	1.00	306.00K	323.00K	136.24K	-3.00	0.00
Net Income	-24.22M	-27.65M	-12.56M	-5.93M	-27.21M	-13.80M	-9.81M	-4.73M	-7.50M	24.18M
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-2.06	-2.43	-1.21	-3.20	-15.80	-21.84	-217.31	-17.42	-32.94	0.00
EPS Diluted	-2.06	-2.43	-1.21	-3.20	-15.80	-21.84	-217.31	-17.42	-32.94	0.00
Weighted Avg Shares Out	11.75M	11.38M	10.37M	1.85M	1.72M	631.70K	45.13K	271.67K	227.69K	50.11B
Weighted Avg Shares Out (Dil)	11.75M	11.38M	10.37M	1.85M	1.72M	631.70K	45.13K	271.67K	227.69K	50.11B

Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)

April 26, 2021prnewswire.com

TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its...